Ondansetron Baxter

Ondansetron, the active ingredient in Ondansetron Baxter, is a 5-HT3 receptor antagonist presented as an injection for intramuscular and intravenous use. It prevents nausea and vomiting associated with chemotherapy, postoperative recovery, and radiation therapy in adult patients.

GNH USA supplies Ondansetron Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes in patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: mitigates nausea associated with therapeutic radiation.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness. - Injection site reactions: pain, erythema, or swelling. - Diarrhoea: occasional loose stools.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Severe allergic reaction: anaphylaxis, rash, or angioedema. - Serotonin syndrome: agitation, hyperthermia, or neuromuscular abnormalities when combined with other serotonergic agents. - Cardiac arrhythmia: irregular heart rhythm. - Hypotension: sudden drop in blood pressure. - Hepatic dysfunction: elevated liver enzymes.

Before initiating therapy, consider patient‑specific risk factors and monitor appropriately. - Cardiac assessment: evaluate baseline ECG in patients with known cardiac disease or electrolyte disturbances. - Electrolyte monitoring: correct hypokalaemia or hypomagnesaemia to reduce QT‑prolongation risk. - Hepatic impairment: use with caution in patients with moderate to severe liver dysfunction. - Drug combinations: avoid concurrent use with apomorphine or other QT‑prolonging agents. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several medications; review concomitant therapy.

Major Interactions (Avoid): - Apomorphine: can cause severe hypotension and loss of consciousness. - Other 5‑HT3 antagonists: additive antiemetic effect may increase risk of cardiac events. - QT‑prolonging drugs (e.g., quinidine, amiodarone): heightened risk of arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Opioids: may increase nausea, requiring dose adjustment. - Anesthetic agents (e.g., propofol): may enhance sedation. - Anticholinergics: may diminish antiemetic efficacy.